Skip to main content

Table 1 Urinary excretion concentration of the anticancer drug and dripping concentration

From: Development and evaluation of adsorption sheet (HD safe sheet-U) using active carbon for the purpose of the preventing the contamination diffusion of urinary excreted anticancer drug

 

Anticancer drug

Dosagea (min ~ max)

Urinary unchanged drug excretion rate (% of dosage/24h)b

Urinary unchanged drug concentrationc (μg/mL)

Dripping concentration (μg/mL)

Alkylating drug

CPA

500mg/m2 – 60mg/kg

10.0

50.0 – 201.2

2,000

IFM

0.8 – 3g/m2

6.0

48.0 – 180.0

1,000

Platinum drug

CBDCA

300 – 635mg/m2

57.0 – 82.0

171.0 – 520.7

5,000

CDDP

10 – 100mg/m2

14.0 – 54.0

1.4 – 54.0

100

Antimetabolite drug

MTX

10mg/body – 300mg/kg

75.0 – 98.0(72h)

1.4 – 3285.5

6,000

5-FU

5mg/kg – 2600mg/m2

10.0

16.8 – 260

1,000

Ara-C

0.8mg/kg – 3,000mg/m2

7.1 – 7.8

1.9 – 234

1,000

GEM

1,000 – 1,250mg/m2

5.3

53.0 – 66.3

300

Anthracycline drug

ADR

0.2mg/kg – 80mg/m2

11.5

0.8 – 9.2

1,000

Epi-ADR

15 – 100mg/m2

6.2 (48h)

0.5 – 3.0

1,000

Taxane drug

PTX

80 – 210mg/m2

7.3 – 11.3(72h)

1.9 – 7.9

200

DTX

60 – 75mg/m2

1.7 – 4.2 (48h)

0.5 – 1.6

200

Topoisomerase inhibitor

VP-16

60 – 500mg/m2

10.3 – 35.2

6.2 – 176.0

500

CPT-11

20 – 180mg/m2

16.3 – 21.1

3.3 – 38.0

1,500

  1. a; Insurance application dose in Japan, b; Report value in each pharmaceutical products IF, c;Dosege × Japanease standard body surface area (1.73m2) or body weight (58kg) × urinary unchanged drug excretion rate ÷standard urine volume (1,730mL/day)